WFH NETWORK

Takeda joins WFH Humanitarian Aid Program

The World Federation of Hemophilia (WFH) is proud to announce that Takeda has joined the WFH Humanitarian Aid Program with a five-year product donation of factor and bypassing agents. This commitment represents a new milestone for Takeda’s collaboration with the WFH. Takeda has supported many WFH programs in the last 30 years, including the World Bleeding Disorder Registry (WBDR) and the Global Alliance for Progress (GAP) Program—the latter since its launch in 2003. With this new commitment, Takeda becomes a WFH Humanitarian Aid Program “Contributor” level sponsor and will provide 15 million IUs of FVIII and 5 million IUs of bypassing agent per year for the next five-years to the WFH.

The WFH Humanitarian Aid Program improves lack of access to care and treatment by providing much-needed support for people with inherited bleeding disorders in developing countries. By providing patients with a more predictable and sustainable flow of humanitarian aid donations, the WFH Humanitarian Aid Program makes it possible for patients to receive consistent and reliable access to treatment and care.

“Takeda has collaborated with the WFH for over 30 years, playing an important role in several of our programs, including the Global Alliance for Progress (GAP) Program and the World Bleeding Disorder Registry (WBDR),” says Alain Baumann, CEO of the WFH. “We are thankful that Takeda has now extended their support to the WFH Humanitarian Aid Program. This will allow the WFH to do even more to support bleeding disorders communities in need around the world.”

Julie Kim—President of the Plasma Derived Therapies Business Unit at Takeda—had this to say about the important milestone in the Takeda’s collaboration with the WFH: “At Takeda we recognize the need to advance the standard of care for those living with a rare bleeding disorder, as well as the importance of tackling disparities in access to treatment worldwide. This five-year product donation aims to help the WFH in improving access to treatment, including prophylaxis to protect joint health. We are pleased to be able to continue collaborating with the WFH on their flagship advocacy and data collection programs, supporting our commitment to achieve a world without bleeds.”

About the WFH Humanitarian Aid Program

The WFH Humanitarian Aid Program improves the lack of access to care and treatment by providing much-needed support for people with inherited bleeding disorders in developing countries. By providing patients with a more predictable and sustainable flow of humanitarian aid donations, the WFH Humanitarian Aid Program makes it possible for patients to receive consistent and reliable access to treatment and care. None of this would be possible without the generous support of Sanofi Genzyme and Sobi, our Founding Visionary Contributors; Bayer, our Visionary Contributor; Grifols and Roche, our Leadership Contributors; and our Contributors, CSL Behring and Takeda.  To learn more about the WFH Humanitarian Aid Program, visit www.treatmentforall.org.

HA Logo